Skip to main content
Premium Trial:

Request an Annual Quote

Doubts

A paper in press in the Journal of Bioterrorism & Biodefense has reignited the debate about the decade-old US anthrax investigation. According to The New York Times, "the new paper raises the prospect — for the first time in a serious scientific forum — that the Army biodefense expert identified by the FBI as the perpetrator, Bruce E. Ivins, had help in obtaining his germ weapons or conceivably was innocent of the crime" he was accused of — mailing letters tainted with dried anthrax spores to politicians and members of the media. The National Academy of Sciences' Alice Gast tells the Times that the potential value of the chemical signatures identified in this new paper had not been fully explored until now. "It just wasn't pursued as vigorously as the microbiology," Gast says. "In interviews, the three authors said their analysis suggested the FBI might have pursued the wrong suspect, and that the case should be reopened," the Times says, adding that "their position may embolden calls for a national commission to investigate the first major bioterrorist attack in American history." This week, the PBS news magazine Frontline — along with ProPublica and the McClatchy Company — digs into the Amerithrax investigation, calling it "the country's most notorious act of bioterrorism."

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.